Table 3.
Min et al. (2015)8 | Suzuki et al. (2016)9 | |||
---|---|---|---|---|
|
|
|||
AI | EI | AI | EI | |
Follow-up period, median, mo | 48 | 83.3 | ||
No. of patients | 1,002 | 313 | 781 | 713 |
Local recurrence | 3 (0.3) | 0 | 0 | 1 (0.14) |
Metastatic recurrence | 0 | 0 | 0 | 2 (0.3) |
Metachronous gastric cancer | 30 (3.0) | 6 (1.9) | 158 (20.2) | 181 (25.4) |
Data are presented as number (%).
AI, absolute indication; EI, expanded indication.